2020-12-10| Asia-PacificIPO

JD Health Debuts in HKEx, Possibly Landing a 3.5 Billion IPO

by Tyler Chen
Share To

The COVID-19 pandemic has hurried the development of telemedicine, precision medicine, and several online platforms. The latest in that line is JD Health, China’s biggest online healthcare platform, which made its debut at HKEx Main Board on December 8th. This IPO is expected to bag 3.48 billion, becoming the second-largest IPO in HKEx in 2020.


Shares Opened higher than Issued Price

JD Health issued 382 million shares, excluding the over-allotment option with 70.58 Hong Kong dollars apiece. On Tuesday, the shares opened to 94.5 Hong Kong dollars each, which is 34% higher than the issued price.

The 6 cornerstone investors included Hillhouse, Tiger Global, Lake Bleu Prime, China Structural Reform Fund, Blackrock, and Singapore’s sovereign wealth fund GIC. will remain the main shareholder after the IPO.


Potentially 2020’s Second Largest IPO in HKEx

JD Health could possibly be the second of the biggest 2020 IPO in HKEx, surpassing China Bohai Bank of 1.78 billion in August., the parent company of JD Health, takes pole position for scoring 4.4 billion in June with a second IPO in HKEx.

In addition, the investment bank can decide to excise the over-allotment option before the end of the year. If it does, JD Health will issue 57 million more shares and possibly add 513 million to the IPO.


Future Plans of Investment

For the future investment plan, JD Health will invest 40% in business expansion over 3 to 5 years, 30% in R&D over 2 to 3 years, and the rest will be used for a potential buyout, investment, and corporate purposes.

By Tyler Chen

Related Article: Aiming for the First CAR-T Approval in China, JW Therapeutics Debuts on Hong Kong Stock Exchange



© All rights reserved. Collaborate with us:
Related Post
GeneOnline’s Top 10 Hong Kong Biotech IPOs of 2021
Experts Discuss What’s Next for Healthcare Innovation and Investment at ASGH
China’s Brii Bio Raises $319 million in the Hong Kong IPO
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top